Literature DB >> 3930839

Differential diagnosis of tetrahydrobiopterin deficiency.

A Niederwieser, A Ponzone, H C Curtius.   

Abstract

Six hundred and seventy-three children (483 newborns and 190 older selected children) were screened for tetrahydrobiopterin (BH4) deficiency by HPLC of urine pterins and BH4 load test. One patient with GTP cyclohydrolase I deficiency, 36 patients with dihydrobiopterin synthetase (DHBS) deficiency (of which six were in the newborn and 30 in the older children) and 14 with dihydropteridine reductase deficiency (DHPR) were found. All 37 patients with defective BH4 biosynthesis responded to a BH4 load by lowering of the elevated serum phenylalanine concentration but four of 14 patients with DHPR deficiency did not. Measurement of DHPR activity in blood spots on Guthrie cards is recommended. Since subvariants of patients with BH4 deficiency exist, homovanillic acid, 5-hydroxyindole acetic acid, pterins, phenylalanine, and tyrosine in cerebrospinal fluid should be measured for diagnosis and the control of therapy. The activity of the phosphate-eliminating enzyme (a key enzyme in BH4 biosynthesis and part of "DHBS") was measured in human liver and activities of approx. 1 n U (mg protein)-1 were found. In the liver biopsy of a patient with DHBS deficiency no activity (less than 3% of controls) was demonstrated.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3930839     DOI: 10.1007/bf01800657

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  31 in total

1.  Malignant hyperphenylalaninaemia--current status (June 1977).

Authors:  D M Danks; K Bartholomé; B E Clayton; H Curtius; H Gröbe; S Kaufman; R Leeming; W Pfleiderer; H Rembold; F Rey
Journal:  J Inherit Metab Dis       Date:  1978       Impact factor: 4.982

2.  Tetrahydropterin therapy for hyperphenylalaninemia caused by defective synthesis of tetrahydrobiopterin.

Authors:  S Kaufman; G Kapatos; W B Rizzo; J D Schulman; L Tamarkin; G R Van Loon
Journal:  Ann Neurol       Date:  1983-09       Impact factor: 10.422

3.  Current status of biopterin screening.

Authors:  R Matalon
Journal:  J Pediatr       Date:  1984-04       Impact factor: 4.406

4.  [Partial deficiency of tetrahydrobiopterin].

Authors:  F Rey; J M Saudubray; R J Leeming; A Niederwieser; H C Curtius; J Rey
Journal:  Arch Fr Pediatr       Date:  1983

5.  Blood spots on Guthrie cards can be used for inherited tetrahydrobiopterin deficiency screening in hyperphenylalaninaemic infants.

Authors:  R J Leeming; P A Barford; J A Blair; I Smith
Journal:  Arch Dis Child       Date:  1984-01       Impact factor: 3.791

6.  Letter: A new molecular defect in phenylketonuria.

Authors:  K Bartholome
Journal:  Lancet       Date:  1974-12-28       Impact factor: 79.321

7.  Analysis of reduced forms of biopterin in biological tissues and fluids.

Authors:  T Fukushima; J C Nixon
Journal:  Anal Biochem       Date:  1980-02       Impact factor: 3.365

8.  Developmental aspects of pteridine metabolism and relationships with phenylalanine metabolism.

Authors:  J L Dhondt; P Ardouin; J M Hayte; J P Farriaux
Journal:  Clin Chim Acta       Date:  1981-10-26       Impact factor: 3.786

9.  Letter: Tetrahydrobiopterin treatment of variant form of phenylketonuria.

Authors:  D M Danks; R G Cotton; P Schlesinger
Journal:  Lancet       Date:  1975-11-22       Impact factor: 79.321

10.  Letter: L-dopa and 5-hydroxytryptophan therapy in phenylketonuria with normal phenylalanine-hydroxylase activity.

Authors:  K Bartholomé; D J Byrd
Journal:  Lancet       Date:  1975-11-22       Impact factor: 79.321

View more
  18 in total

1.  Study design and description of patients.

Authors:  P Lutz; H Schmidt; U Batzler
Journal:  Eur J Pediatr       Date:  1990       Impact factor: 3.183

2.  Neurotransmitter therapy and diet in malignant phenylketonuria.

Authors:  A Ponzone; O Guardamagna; S Ferraris; S Biasetti; G Bracco; A Niederwieser
Journal:  Eur J Pediatr       Date:  1987-01       Impact factor: 3.183

3.  A simple and sensitive method for the determination of pterins in cerebrospinal fluid. Clinical usefulness for management of tetrahydrobiopterin deficiency.

Authors:  K Suzuki; M Owada
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

4.  Treatment and outcome of Taiwanese patients with 6-pyruvoyltetrahydropterin synthase gene mutations.

Authors:  Y H Chien; S C Chiang; A Huang; J M Lin; Y N Chiu; S P Chou; S Y Chu; T R Wang; W L Hwu
Journal:  J Inherit Metab Dis       Date:  2001-12       Impact factor: 4.982

5.  Dihydropteridine reductase activity in eluates from dried blood spots: automation of an assay for a national screening service.

Authors:  I M Surplice; P D Griffiths; A Green; R J Leeming
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

6.  Possible high frequency of tetrahydrobiopterin deficiency in south Brazil.

Authors:  L B Jardim; R Giugliani; J C Coelho; C S Dutra-Filho; N Blau
Journal:  J Inherit Metab Dis       Date:  1994       Impact factor: 4.982

7.  Blood phenylalanine concentrations in patients with PAH-deficient hyperphenylalaninaemia off diet without and with three different single oral doses of tetrahydrobiopterin: assessing responsiveness in a model of statistical process control.

Authors:  M Lindner; G Gramer; S F Garbade; P Burgard
Journal:  J Inherit Metab Dis       Date:  2009-06-10       Impact factor: 4.982

8.  Neuropsychiatric Symptoms in Inborn Errors of Metabolism: Incorporation of Genomic and Metabolomic Analysis into Therapeutics and Prevention.

Authors:  Lisa Pan; Jerry Vockley
Journal:  Curr Genet Med Rep       Date:  2013-01-08

9.  Differential diagnosis of hyperphenylalaninaemia by a combined phenylalanine-tetrahydrobiopterin loading test.

Authors:  A Ponzone; O Guardamagna; M Spada; S Ferraris; R Ponzone; L Kierat; N Blau
Journal:  Eur J Pediatr       Date:  1993-08       Impact factor: 3.183

10.  Classifying tetrahydrobiopterin responsiveness in the hyperphenylalaninaemias.

Authors:  U Langenbeck
Journal:  J Inherit Metab Dis       Date:  2008-01-22       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.